ReviewRadiology2022
Ductal Carcinoma in Situ: State-of-the-Art Review.
Review in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07439432 (Stereotactic Guided Biopsy and Cryoablation of Breast Cancer), which is not on this map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Stereotactic Guided Biopsy and Cryoablation of Breast Cancer
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Artificial intelligence in the radiologic assessment of ductal carcinomaFrontiers in oncology · 2026Pooled it
- MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial).Radiology · 2025Trial
- Recruiting women with ductal carcinoma in situ to a randomised controlled trial: lessons from the LORIS study.Trials · 2023Trial
- Channel attention of the image for distinguishing ductal carcinomaGland surgery · 2026Article
- Prognostic Implications of Calcification and Surgery Type by Estrogen Receptor and HER2 Status in Ductal CarcinomaJournal of breast cancer · 2026Article
- Impact of Contrast-Enhanced Mammography on Personalized Surgical Decision-Making in Ductal Carcinoma In Situ: A Multicentre Pilot Observational Cohort Study.Journal of personalized medicine · 2026Article
- Comment on "Cancer risk among women with scoliosis: a nationwide Danish register-based study".Spine deformity · 2026Article
- Article
- Integrating multi-omics and clinical management in breast cancer: a comprehensive review.Discover oncology · 2026Review
- Recurrence Patterns and Overtreatment in Pure DCIS: A Retrospective Clinical and Radiological Follow-Up Study.Journal of personalized medicine · 2026Article
- Beyond Histology: Evaluating Ultrafast DCE MRI Texture Analysis for Breast DCIS Grading.Radiology. Imaging cancer · 2026Article
- Stereotactic Vacuum-Assisted Biopsy in Photon-Counting Dedicated Spiral Breast CT: A Proof of Concept.Geburtshilfe und Frauenheilkunde · 2026Article
- Labels, Language and Other Strategies to Improve Communication About Lowest Grade Ductal Carcinoma in Situ: Qualitative Interviews With Women and Physicians.Psycho-oncology · 2026Article
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.Breast care (Basel, Switzerland) · 2026Review
- Imaging Ductal Carcinoma In Situ in the Era of De-Escalation: Role, Limits, and Clinical Implications for Risk-Adapted Management.Diagnostics (Basel, Switzerland) · 2026Review
- Automated Cluster-based Quantitative Analysis of Ultrafast DCE MRI for Differential Breast DCIS Grading.Radiology. Imaging cancer · 2026Article
- Multiparametric breast MRI to problem-solve mammographically detected suspicious calcifications.European journal of radiology · 2026Article
- Influence of follow-up, screening age, interval, and compliance on overdiagnosis of ductal carcinoma in situ (DCIS): A modelling study.PloS one · 2026Article
- Prediction of histological grading in ductal carcinomaFrontiers in oncology · 2026Article
- Semaphorin-7A promotes macrophage-mediated mammary epithelial and ductal carcinoma in situ invasion.Breast cancer research : BCR · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Ductal carcinoma in situ (DCIS) is a nonobligate precursor of invasive cancer, and its detection, diagnosis, and management are controversial. DCIS incidence grew with the expansion of screening mammography programs in the 1980s and 1990s, and DCIS is viewed as a major driver of overdiagnosis and overtreatment. For pathologists, the diagnosis and classification of DCIS is challenging due to undersampling and interobserver variability. Understanding the progression from normal breast tissue to DCIS and, ultimately, to invasive cancer is limited by a paucity of natural history data with multiple proposed evolutionary models of DCIS initiation and progression. Although radiologists are familiar with the classic presentation of DCIS as asymptomatic calcifications at mammography, the expanded pool of modalities, advanced imaging techniques, and image analytics have identified multiple potential biomarkers of histopathologic characteristics and prognosis. Finally, there is growing interest in the nonsurgical management of DCIS, including active surveillance, to reduce overtreatment and provide patients with more personalized management options. However, current biomarkers are not adept at enabling identification of occult invasive disease at biopsy or accurately predicting the risk of progression to invasive disease. Several active surveillance trials are ongoing and are expected to better identify women with low-risk DCIS who may avoid surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.